| Symbol | IMMX |
|---|---|
| Name | IMMIX BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11400 WEST OLYMPIC BOULEVARD,SUITE 200, LOS ANGELES, California, 90064, United States |
| Telephone | +1 310 651-8041 |
| Fax | — |
| — | |
| Website | https://www.immixbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001873835 |
| Description | Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Immix Biopharma, Inc. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001274173-26-000156 <b>Size:</b> 12 KB
Read moreDirector Adams Helen C. 🟢 acquired 18.8K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 Transaction Date: May 22, 2026 | Filing ID: 026429
Read moreDirector Ng Carey 🟢 acquired 18.8K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 Transaction Date: May 22, 2026 | Filing ID: 026430
Read moreDirector Marquet Magda 🟢 acquired 18.8K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 Transaction Date: May 22, 2026 | Filing ID: 026427
Read moreDirector Morris Gabriel S 🟢 acquired 500.0K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 ($4.4M) Transaction Date: May 22, 2026 | Filing ID: 026428
Read moreDirector CHANG NANCY T 🟢 acquired 18.8K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 Transaction Date: May 22, 2026 | Filing ID: 026426
Read moreDirector Rachman Ilya M 🟢 acquired 500.0K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 ($4.4M) Transaction Date: May 22, 2026 | Filing ID: 026425
Read moreDirector Chudnovsky Yekaterina 🟢 acquired 18.8K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 Transaction Date: May 22, 2026 | Filing ID: 026424
Read moreDirector Hsu Jason 🟢 acquired 18.8K shares (1 derivative) of Immix Biopharma, Inc. (IMMX) at $8.78 Transaction Date: May 22, 2026 | Filing ID: 026422
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06097832 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Phase1 | Light Chain (AL) Amyloidosis | Recruiting | 2024-06-05 | 2039-01-01 | ClinicalTrials.gov |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Sol… | Phase1 | Advanced Solid Tumor | Unknown | 2023-02-03 | 2024-01-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| IMX-110 combined with Tislelizumab | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05840835 |
| NXC-201 CAR-T | Other | Phase PHASE1 | Light Chain (AL) Amyloidosis | RECRUITING | NCT06097832 |
| NXC-201 CAR-T | BIOLOGICAL | Phase PHASE1 | Light Chain (AL) Amyloidosis | RECRUITING | NCT06097832 |
| IMX-110 combined with Tislelizumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05840835 |